Frank TufaroBSc, PhD
Frank Tufaro has extensive experience with the founding, financing, and operation of biotechnology firms. Prior to DNAtrix, Frank was part of the founding team of NeuroVir, a Vancouver-based biotech company with a mission to develop herpes-simplex virus oncolytic vectors for treating cancer. Frank was instrumental in raising venture financing that established NeuroVir as the major player in the field of viral oncology and led to its acquisition by MediGene.
Frank also co-founded Nurel Therapeutics, a gene therapy company acquired by Diamyd Medical AB, and Allera Health Products. Previously, Frank was a Professor of Microbiology at the University of British Columbia, wherein his laboratory worked on herpes simplex virus and gene therapy for cancer. Frank received his BSc in Cell and Molecular Biology, a PhD in Developmental Biology from McGill University and was a postdoctoral fellow with Dr. Steve McKnight, at the Fred Hutchinson Cancer Center and the Carnegie Institution of Science.